Anti-integrin Beta-1 Monoclonal Antibody OS2966

A humanized monoclonal antibody directed against the human integrin receptor beta-1 subunit (CD29), with potential antineoplastic activity. Upon administration, anti-integrin beta-1 monoclonal antibody OS2966 targets and binds to integrin beta-1 on the surface of tumor cells and macrophages in the tumor microenvironment (TME), thereby preventing integrin beta-1-mediated activation of downstream signaling pathways. This may include the blockade of the binding of integrin beta-1 to the effector kinase focal adhesion kinase (FAK), preventing FAK-mediated activation of Stat1 and Akt. This may inhibit tumor cell proliferation, invasion and migration in integrin beta-1-overexpressing tumor cells. Integrin beta-1, the dominant subunit in all four classes of integrin receptors, plays an important role in tumor cell proliferation, invasion, and drug resistance.